КФУ. Карточка публикации. Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports

RUS

- EN
- 中文
- ES

GENE THERAPY USING PLASMID DNA ENCODING BONE MORPHOGENETIC PROTEIN 2 AND VASCULAR ENDOTHELIAL GROWTH FACTOR 164 GENES FOR THE TREATMENTOF EQUINE PROXIMAL SUSPENSORY DESMITIS: CASE REPORTS

Форма представления

Статьи в российских журналах и сборниках

Год публикации

2024

Язык

английский

Авторы, сотрудники КФУ

Аймалетдинов Александр Маазович, автор

Закирова Елена Юрьевна, автор

Ризванов Альберт Анатольевич, автор

Библиографическое описание на языке оригинала

Kovac M. Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports / M. Kovac, I. V. Berestov, A. M. Aimaletdinov [et al.] // Opera Medica et Physiologica. – 2024. – Vol. 11, No. 2. – P. 74-89. – DOI 10.24412/2500-2295-2024-2-74-89

Аннотация

Injury to the proximal part of the equine suspensory ligament (SL), called proximal suspensory desmitis (PSD), commonly causes lameness in horses. PSD is extremely difficult to manage and treat, with present methods often unable to achieve full recovery, especially in chronic cases. The present study was the first to use gene therapy to restore moderate and severe injuries of the proximal suspensory ligament in horses. Plasmid DNA encoding species specific bone morphogenetic protein 2 ( bmp2 ) and vascular endothelial growth factor ( vegf164 ) was injected into the site of proximal suspensory ligament injury, followed by box rest and a controlled exercise program. Clinical observations and ultrasound imaging were used to evaluate effectiveness over a period of 12 months. No negative side effects were observed. Clinical improvements were observed, especially in the forelimb affected horses, by day 30. In horses with chronic hindlimb PSD, few clinical improvements were reported. Echogenicity and the fiber alignment scoring improved but no concomitant changes to cross section area, dorsopalmar thickness or lateromedial width of the proximal suspensory ligament were observed. The transfer of bmp2 and vegf164 genes into the equine PSL exhibited beneficial effects in horses with acute or subacute forms of lesions, primarily in the forelimb.

Ключевые слова

PROXIMAL SUSPENSORY DESMITIS, PLASMID DNA, BONE MORPHOGENETIC PROTEIN 2, VASCULAR ENDOTHELIAL GROWTH FACTOR

Название журнала

Opera Medica et Physiologica

Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку

https://repository.kpfu.ru/?p_id=315896

Файлы ресурса

Название файла	Размер (Мб)	Формат
F_07_Zakirova_74_89.pdf	1,15	pdf	посмотреть / скачать

Полная запись метаданных

Поле DC	Значение	Язык
dc.contributor.author	Аймалетдинов Александр Маазович	ru_RU
dc.contributor.author	Закирова Елена Юрьевна	ru_RU
dc.contributor.author	Ризванов Альберт Анатольевич	ru_RU
dc.date.accessioned	2024-01-01T00:00:00Z	ru_RU
dc.date.available	2024-01-01T00:00:00Z	ru_RU
dc.date.issued	2024	ru_RU
dc.identifier.citation	Kovac M. Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports / M. Kovac, I. V. Berestov, A. M. Aimaletdinov [et al.] // Opera Medica et Physiologica. – 2024. – Vol. 11, No. 2. – P. 74-89. – DOI 10.24412/2500-2295-2024-2-74-89	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/?p_id=315896	ru_RU
dc.description.abstract	Opera Medica et Physiologica	ru_RU
dc.description.abstract	Injury to the proximal part of the equine suspensory ligament (SL), called proximal suspensory desmitis (PSD), commonly causes lameness in horses. PSD is extremely difficult to manage and treat, with present methods often unable to achieve full recovery, especially in chronic cases. The present study was the first to use gene therapy to restore moderate and severe injuries of the proximal suspensory ligament in horses. Plasmid DNA encoding species specific bone morphogenetic protein 2 ( bmp2 ) and vascular endothelial growth factor ( vegf164 ) was injected into the site of proximal suspensory ligament injury, followed by box rest and a controlled exercise program. Clinical observations and ultrasound imaging were used to evaluate effectiveness over a period of 12 months. No negative side effects were observed. Clinical improvements were observed, especially in the forelimb affected horses, by day 30. In horses with chronic hindlimb PSD, few clinical improvements were reported. Echogenicity and the fiber alignment scoring improved but no concomitant changes to cross section area, dorsopalmar thickness or lateromedial width of the proximal suspensory ligament were observed. The transfer of bmp2 and vegf164 genes into the equine PSL exhibited beneficial effects in horses with acute or subacute forms of lesions, primarily in the forelimb.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	PROXIMAL SUSPENSORY DESMITIS	ru_RU
dc.subject	PLASMID DNA	ru_RU
dc.subject	BONE MORPHOGENETIC PROTEIN 2	ru_RU
dc.subject	VASCULAR ENDOTHELIAL GROWTH FACTOR	ru_RU
dc.title	Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports	ru_RU
dc.type	Статьи в российских журналах и сборниках	ru_RU